Among the retinoic acid receptors (RARα, RARβ and RARγ), the co-administration of ATRA with arsenic trioxide represents a breakthrough front-line treatment for acute promyelocytic leukemia, acting via modulation of RARα activity, offering new avenues for effectively managing the disease (Ma et al., 2016). The gene discussed is RARB; the disease is acute promyelocytic leukemia.